Sidley represented Precision NeuroMed Inc. in its strategic partnership with Brainlab SE under a Joint Development and Commercialization Agreement. This strategic partnership was entered into on 2026-02-27.
Under the agreement, the companies will collaborate to develop and commercialize a cloud-based, AI-enabled treatment planning platform for convection enhanced delivery to the brain, and Brainlab has also received an equity interest in Precision NeuroMed.
Precision NeuroMed is a clinical-stage biotechnology company advancing precision therapeutics for central nervous system diseases, and the platform is intended to support more precise and personalized drug delivery to brain tissue.